In quest to beat COVID-19, Bay Area biotech closes Big Pharma equity deal for $250M
April 06, 2020 at 10:31 AM EDT
The companies hope to push two antibodies into mid-stage clinical trials within three to five months.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|